Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: Adenovirus Infection, EBV Infection
Interventions: Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Coral Gables, Florida • Boston, Massachusetts + 3 more

Conditions: Infectious Diseases
Interventions: Ciprofloxacin, Non-quinolone antibiotic; Drug
Lead sponsor: Bayer; Industry
Eligibility: 2 Months to 16 Years
Enrollment: 1,029 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 66
States / cities: Mobile, Alabama • Fort Smith, Arkansas • Corona, California + 58 more

Conditions: Hiv, Adolescent Behavior, Family Relations, Sexual Orientation
Interventions: MySTYLE, Waitlist Control; Behavioral · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 14 Years to 20 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Intra-amniotic Infection
Interventions: Not listed
Lead sponsor: ProteoGenix, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 21
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 16 more

Conditions: Papilloma Viral Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 17 Years · Female only
Enrollment: 1,321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Tucker, Georgia • Baltimore, Maryland • Kansas City, Missouri + 4 more

Conditions: Non-Infectious Uveitis
Interventions: FAI insert, Sham injection; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 16
States / cities: Beverly Hills, California • Sacramento, California • Torrance, California + 13 more

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Methotrexate, Leucovorin calcium, Zidovudine, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Uveitis
Interventions: Izokibep, Prednisone/Prednisolone; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Hagerstown, Maryland + 1 more

Conditions: COVID-19 Infection
Interventions: Brequinar, Placebo; Drug
Lead sponsor: Clear Creek Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 18
States / cities: Birmingham, Alabama • San Francisco, California • San Jose, California + 11 more

Conditions: Cirrhosis
Interventions: Not listed
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions: Allodepleted T Cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Vaginal Odor
Interventions: WaterWorks Douching Device; Device
Lead sponsor: Abbott Research Group; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Aventura, Florida • Plantation, Florida • Atlanta, Georgia + 4 more

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: etanercept, methylprednisolone; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more

Conditions: Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
Interventions: triamcinolone acetonide (Triesence®); Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio

Conditions: Gram-negative Bacterial Infection
Interventions: Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 39 Weeks
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more

Conditions: Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
Interventions: Blood draw and IGRA test; Diagnostic Test
Lead sponsor: BioMérieux; Industry
Eligibility: 2 Years and older
Enrollment: 2,401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 4 more

Conditions: Dysentery, Bacillary
Interventions: S.sonnei vaccine, Placebo, S. sonnei 53G challenge strain; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 58
States / cities: Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Groton, Connecticut

Conditions: Warts, Warts Hand, Verruca
Interventions: CellFX System Device, Cryosurgery Liquid Nitrogen Sprayer; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Scottsdale, Arizona • Beverly Hills, California • Greenwood Village, Colorado + 7 more

Conditions: Human Immunodeficiency Virus Type 1
Interventions: TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 9
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more

Conditions: Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Refractory Anemia
Interventions: Fludarabine, Cyclophosphamide, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Dilanubicel; Drug · Radiation · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 5
States / cities: San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Search by objective public record fields.

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South

Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes

Immunogenicity of Off-Schedule Dosing of HPV Vaccine

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

Evaluation of Patients Who Have Not Had Success With Zidovudine

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene

Efficacy of (WaterWorks®)Douching Device for Elimination of Perceived Vaginal Odor Not Caused by BV or Vaginitis

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Performance Evaluation of the VIDAS TB-IGRA Assay.

A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures